Suvretta Capital Takes 5.0% Stake in Cogent Biosciences

TL;DR

**Suvretta Capital just bought 5% of Cogent Biosciences, signaling a bullish institutional bet.**

AI Summary

Suvretta Capital Management, LLC, a Delaware-based investment firm, reported a significant stake in Cogent Biosciences, Inc. (NASDAQ: COGT) as of January 26, 2024. This SC 13G filing indicates that Suvretta Capital Management now beneficially owns 5.0% of Cogent Biosciences' Common Stock, specifically 3,190,000 shares. This matters to investors because a major institutional investor taking a 5% stake can signal confidence in the company's future prospects, potentially influencing other investors and the stock price.

Why It Matters

A new 5.0% stake by Suvretta Capital Management could be seen as a vote of confidence in Cogent Biosciences, potentially attracting more investor interest and positively impacting the stock.

Risk Assessment

Risk Level: low — This filing indicates an institutional investor has taken a significant stake, which is generally a positive signal and not inherently risky.

Analyst Insight

A smart investor would research Suvretta Capital Management's investment thesis and Cogent Biosciences' fundamentals to understand the potential drivers behind this institutional investment, considering it as a positive signal.

Key Numbers

• 5.0% — Percentage of Class Owned (Represents the beneficial ownership stake Suvretta Capital Management, LLC holds in Cogent Biosciences, Inc.)
• 3,190,000 — Shares Beneficially Owned (The total number of Common Stock shares of Cogent Biosciences, Inc. owned by Suvretta Capital Management, LLC.)
• 19240Q201 — CUSIP Number (Unique identifier for Cogent Biosciences, Inc.'s Common Stock.)

Key Players & Entities

• Suvretta Capital Management, LLC (company) — the reporting person, an investment firm
• Cogent Biosciences, Inc. (company) — the subject company, a pharmaceutical preparations company
• 3,190,000 (dollar_amount) — number of shares beneficially owned by Suvretta Capital Management, LLC
• January 26, 2024 (date) — date of the event requiring the filing
• Delaware (company) — state of organization for Suvretta Capital Management, LLC

Forward-Looking Statements

• Cogent Biosciences' stock price may experience increased investor interest and potentially upward movement due to Suvretta Capital Management's new stake. (Cogent Biosciences, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securiti

Filing Documents

• d10938931_13-g.htm (SC 13G) — 117KB
• 0000919574-24-000675.txt ( ) — 118KB

From the Filing

SC 13G 1 d10938931_13-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Cogent Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 19240Q201 (CUSIP Number) January 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 19240Q201 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Suvretta Capital Management, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 5,481,034 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 5,481,034 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,481,034 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.4% 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA, OO CUSIP No. 19240Q201 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Averill Master Fund, Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 4,868,640 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 4,868,640 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,868,640 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.7% 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 19240Q201 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Aaron Cowen 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 5,481,034 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 5,481,034 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,481,034 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.4% 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN, HC CUSIP No. 19240Q201 Item 1. (a). Name of Issuer: Cogent Biosciences, Inc. (b). Address of Issuer's Principal Executive Offices: 275 Wyman Street, 3rd Floor Waltham, Massachusetts 02451 Item 2. (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing: Suvretta Capital Management, LLC – Delaware Averill Master Fund, Ltd. – Cayman Islands Aaron Cowen – U.S.A. Suvretta Capital Management, LLC : 540 Madison Avenue, 7th Floor New York, New York 10022 United States of America Averill Master Fund, Ltd.: c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen : c/o Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022 (d). Title of Class of Securities: Common Stock, $0.001 Par Value (the “Common Stock”) (e). CUSIP Number: 19240Q201 Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c). (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c). (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c). (d) [_] Investmen

View Full Filing

View this SC 13G filing on SEC EDGAR